Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the sale, the chief operating officer now owns 617,470 shares in the company, valued at approximately $7,193,525.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Roivant Sciences Trading Down 0.9 %
NASDAQ ROIV opened at $11.62 on Thursday. The firm has a market capitalization of $8.58 billion, a price-to-earnings ratio of 2.30 and a beta of 1.24. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. Roivant Sciences Ltd. has a one year low of $8.24 and a one year high of $13.06. The company’s 50 day moving average price is $11.79 and its 200 day moving average price is $11.22.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The business had revenue of $55.10 million for the quarter, compared to the consensus estimate of $30.72 million. During the same quarter last year, the firm posted ($0.38) EPS. The business’s revenue for the quarter was up 155.1% compared to the same quarter last year. On average, sell-side analysts predict that Roivant Sciences Ltd. will post -1.14 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. Piper Sandler lifted their price target on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Thursday, September 19th. Finally, Bank of America raised their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.39.
Get Our Latest Stock Analysis on Roivant Sciences
Roivant Sciences Company Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
- Five stocks we like better than Roivant Sciences
- How to Plot Fibonacci Price Inflection Levels
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Investing in the High PE Growth Stocks
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- The 3 Best Blue-Chip Stocks to Buy Now
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.